MDM2 Antibodies

Santa Cruz Biotechnology supplies a comprehensive collection of MDM2 monoclonal antibodies for investigating MDM2 protein functions in cellular processes. MDM2 monoclonal antibodies are compatible with multiple research applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). MDM2 is a critical negative regulator of the p53 tumor suppressor, playing a vital role in cell cycle regulation and apoptosis. By binding to p53, MDM2 promotes its degradation, thereby influencing cellular responses to stress and DNA damage. Dysregulation of MDM2 has been implicated in various cancers, making MDM2 a significant target for therapeutic intervention. MDM2 research continues to reveal new insights into cancer development and progression. Understanding MDM2's interaction with p53 and other cellular proteins is essential for developing targeted cancer therapies. Current research focuses on exploring MDM2's role in different cancer types and its potential as a therapeutic target. Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance cancer biology understanding and contribute to the development of new therapeutic strategies.